TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary

Participants were * administered study medication approximately 28 days after initial surgery for ovarian cancer * received the study treatment regimen of up to one year unless there was disease progression, unacceptable toxicity, death, participant refusal, or treatment delay beyond the time frame permitted for each treatment Participants were followed for survival for a minimum 3 years from the date of enrollment